Carley ME, Gonzalez Bosquet J, Stanhope CR. Small bowel obstruction associated with post-hysterectomy vaginal vault prolapse. Obstet Gynecol 2003;102:524–526.

Carley ME, Rickard DJ, Gebhart JB, Webb MJ, Podratz KC, Spelsberg TC. Distribution of estrogen receptors alpha and beta mRNA in mouse urogenital tissues and their expression after oophorectomy and estrogen replacement. Int Urogynecol J Pelvic Floor Dysfunct 2003;14:141–145.

Lawson Y, Dombrowski MP, Carter S, Hagglund KH. Does external tocodynamometry increase maternal perception of uterine contractions? Am J Obstet Gynecol 2003;189:1396–1397.

Oncology, Hematology and Oncological Surgery

Buzdar A, O'Shaughnessy JA, Booser DJ, Pippen JE Jr, Jones SE, Munster PN, Peterson P, Melemed AS, Winer E, Hudis C. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol 2003;21:1007–1014.

Edelman J, Edelman J, Nemunaitis J. Adenoviral p53 gene therapy in squamous cell cancer of the head and neck region. Curr Opin Mol Ther 2003;5:611–617.

Fant J, Grant M, May S, Talaasen L, Watkins D. Angiosarcoma of the breast: mammographic, clinical, and pathologic correlation. Breast J 2003;9:252–253.

Jones SE. Fulvestrant: an estrogen receptor antagonist that downregulates the estrogen receptor. Semin Oncol 2003;30(5 Suppl 16):14–20.

Joppert MG, Garfield DH, Gregurich MA, Nemunaitis JJ, Marsland TA, Khandelwal P, Asmar L. A phase II multicenter study of combined topotecan and gemcitabine as first line chemotherapy for advanced non–small cell lung cancer. Lung Cancer 2003;39:215–219.

Kelloff GJ, O'Shaughnessy JA, Gordon GB, Hawk ET, Sigman CC. Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers. Cancer Epidemiol Biomarkers Prev 2003;12:593–596.

Kyle RA, Treon SP, Alexanian R, Barlogie B, Bjorkholm M, Dhodapkar M, Lister TA, Merlini G, Morel P, Stone M, Branagan AR, Leblond V. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:116–120.

Leyland-Jones B, O'Shaughnessy JA. Erythropoietin as a critical component of breast cancer therapy: survival, synergistic, and cognitive applications. Semin Oncol 2003;30(5 Suppl 16):174–184.

Linker C, Anderlini P, Herzig R, Christiansen N, Somlo G, Bensinger W, Fay J, Lynch JP, Goodnough LT, Ashby M, Benyunes MC, Jones DV, Yang TA, Miller LL, Weaver C. Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation. Biol Blood Marrow Transplant 2003;9:405–413.

Metayer C, Curtis RE, Vose J, Sobocinski KA, Horowitz MM, Bhatia S, Fay JW, Freytes CO, Goldstein SC, Herzig RH, Keating A, Miller CB, Nevill TJ, Pecora AL, Rizzo JD, Williams SF, Li CY, Travis LB, Weisdorf DJ. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 2003;101:2015–2023.

Nemunaitis J. GVAX (GMCSF gene modified tumor vaccine) in advanced stage non–small cell lung cancer. J Control Release 2003;91:225–231.

Nemunaitis J. Selective replicating viral vectors: potential for use in cancer gene therapy. BioDrugs 2003;17:251–262.

Nemunaitis J, Cunningham C, Senzer N. Enhanced oncolytic potency of replicative adenovirus expressing p53. Drug Resist Updat 2003;6:5–7.

Nemunaitis J, Cunningham C, Senzer N, Kuhn J, Cramm J, Litz C, Cavagnolo R, Cahill A, Clairmont C, Sznol M. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther 2003;10:737–744.

Nemunaitis J, Cunningham C, Tong AW, Post L, Netto G, Paulson AS, Rich D, Blackburn A, Sands B, Gibson B, Randlev B, Freeman S. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther 2003;10:341–352.

Nemunaitis J, Nemunaitis J. Granulocyte-macrophage colony-stimulating factor gene-transfected autologous tumor cell vaccine: focus on non–small-cell lung cancer. Clin Lung Cancer 2003;5:148–157.

Nemunaitis JJ, Orr D, Eager R, Cunningham CC, Williams A, Mennel R, Grove W, Olson S. Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer. Cancer J 2003;9:58–66.

O'Shaughnessy J. Chemotherapy-related cognitive dysfunction in breast cancer. Semin Oncol Nurs 2003;19(4 Suppl 2):17–24.

O'Shaughnessy J. Gemcitabine and trastuzumab in metastatic breast cancer. Semin Oncol 2003;30(2 Suppl 3):22–26.

O'Shaughnessy J. Liposomal anthracyclines for breast cancer: overview. Oncologist 2003;8(Suppl 2):1–2.

O'Shaughnessy JA. Breast cancer vaccines. Clin Breast Cancer 2003;3(Suppl 4):S133.

O'Shaughnessy JA. Chemotherapy-induced cognitive dysfunction: a clearer picture. Clin Breast Cancer 2003;4(Suppl 2):S89–S94.

O'Shaughnessy JA. Ductal lavage: clinical utility and future promise. Surg Clin North Am 2003;83:753–769.

O'Shaughnessy JA. Emerging strategies in the management of breast cancer. Clin Breast Cancer 2003;4(Suppl):S8–S9.

O'Shaughnessy JA. The evolving role of capecitabine in breast cancer. Clin Breast Cancer 2003;4(Suppl 1):S20–S25.

O'Shaughnessy JA. Pegylated liposomal doxorubicin in the treatment of breast cancer. Clin Breast Cancer 2003;4:318–328.

Roberts S, Miller J, Pineiro L, Jennings L. Total parenteral nutrition vs oral diet in autologous hematopoietic cell transplant recipients. Bone Marrow Transplant 2003;32:715–721.

Senzer N, Hanna N, Vijayakumar S, Mani S, Mundt A, Nemunaitis J, Rosemurgy A, Cunningham C, Schwartz H, Guha C, Peabody T, Bayol N, Das Gupta T, Rasmussen H, Chu K, Gillen M, Rasmussen C, Weichselbaum R. Selective radiosensitization with TNFerade, a radiation-inducible tumor necrosis factor-a (TNFa) gene transfer vector: phase 1 evaluations. Int J Radiat Oncol Biol Phys 2003;55:466–470.

Stone MJ, McElroy YG, Pestronk A, Reynolds JL, Newman JT, Tong AW. Human monoclonal macroglobulins with antibody activity. Semin Oncol 2003;30:318–324.

Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML, Goel A, Barbieri V, Costanzo F, Boland CR, Venuta S. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003;88:1285–1291.

Tong AW, Stone MJ. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 2003;10:1–13.

Zujewski JA, Eng-Wong J, O'Shaughnessy J, Venzon D, Chow C, Danforth D, Kohler DR, Cusack G, Riseberg D, Cowan KH. A pilot study of dose intense doxorubicin and cyclophosphamide followed by infusional paclitaxel in high-risk primary breast cancer. Breast Cancer Res Treat 2003;81:41–51.

Ophthalmology

El-Agha MS, Bowman RW, Cavanagh D, McCulley JP. Comparison of photorefractive keratectomy and laser in situ keratomileusis for the treatment of compound hyperopic astigmatism. J Cataract Refract Surg 2003;29:900–907.

El-Agha MS, Johnston EW, Bowman RW, Cavanagh HD, McCulley JP. Photorefractive keratectomy versus laser in situ keratomileusis for the treatment of spherical hyperopia. Eye Contact Lens 2003;29:31–37.

Holden BA, Secor G, Weisbarth R, Driebe W, McCulley JP, Becherer D. Rigid lenses, soft lenses, or LASIK: which would you chose? Discussion and summary. Eye & Contact Lens: Science and Clinical Practice 2003;29:S143–S144.

McCulley JP. Biocompatibility of intraocular lenses. Eye Contact Lens 2003;29:155–163.

McCulley JP, Shine WE. Eyelid disorders: the meibomian gland, blepharitis, and contact lenses. Eye Contact Lens 2003;29(1 Suppl):S93–S95.

McCulley JP, Shine WE. Meibomian gland function and the tear lipid layer. The Ocular Surface 2003;1(3):97–106.

Mendelblatt D, McCulley JP, Bowman RW, Verity S, Cavanagh HD. Effects of an educational seminar on rejection demographics in patients presenting for laser in situ keratomileusis. Eye Contact Lens 2003;29:69–71.

Schwab IR, Friedlaender M, McCulley J, Lichtenstein SJ, Moran CT; Levofloxacin Bacterial Conjunctivitis Active Control Study Group. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Ophthalmology 2003;110:457–465.

Seward MS, Oral D, Bowman RW, El-Agha MS, Cavanagh HD, McCulley JP. Comparison of LADARVision and Visx Star S3 laser in situ keratomileusis outcomes in myopia and hyperopia. J Cataract Refract Surg 2003;29:2351–2357.

Shine WE, McCulley JP. Polar lipids in human meibomian gland secretions. Curr Eye Res 2003;26:89–94.

Shine WE, McCulley JP, Pandya AG. Minocycline effect on meibomian gland lipids in meibomianitis patients. Exp Eye Res 2003;76:417–420.

Ta CN, Shine WE, McCulley JP, Pandya A, Trattler W, Norbury JW. Effects of minocycline on the ocular flora of patients with acne rosacea or seborrheic blepharitis. Cornea 2003;22:545–548.

Vargas JM, McCulley JP, Bowman RW, Johnston EW, Jani BR, Shen J. Effect of phacoemulsification on corneal thickness. Am J Ophthalmol 2003;136:171–172.

Whitson JT, McCulley JP, Cavanagh HD, Song J, Bowman RW, Hertzog L. Effect of laser in situ keratomileusis on optic nerve head topography and retinal nerve fiber layer thickness. J Cataract Refract Surg 2003;29:2302–2305.